Beta-blockers for heart failure: why, which, when, and where.
Beta-blockers are a highly effective treatment for patients with all grades of heart failure secondary to LV systolic dysfunction. Beta-blockers are best deployed as a form of tertiary prevention in heart failure but have a very limited role for the treatment of a heart failure crisis. Physicians and patients need to understand the time course of the effects of beta-blocker therapy. The initial effects are often neutral or adverse, though the benefits, at least of carvedilol, may be apparent within days in patients with severe heart failure. Benefits accumulate gradually over a period of weeks to months. Some patience, perseverance, and education are required in order to allow patients to reap the full benefits of beta-blocker therapy for this malignant disease. Initiation of treatment early in the course of the disease maximizes the effectiveness and acceptance of therapy. Trials are under way to determine whether the benefits of beta-blockers extend to patients over 80 years of age and to those with preserved LV systolic function. It is likely that important differences exist between beta-blockers in terms of their clinical benefit, though whether differences exist between the agents that have been reported to be effective so far awaits the outcome of a large clinical trial. It is unclear whether the target doses of beta-blockers currently recommended are optimal.
Cleland
John G F
JG
Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom. j.g.cleland@medschool.hull.ac.uk
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D000367:Age Factors; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D000075202:Contraindications; D004334:Drug Administration Schedule; D006333:Heart Failure / Q000188:drug therapy* / Q000208:ethnology / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013318:Stroke Volume / Q000187:drug effects; D016896:Treatment Outcome; D016276:Ventricular Function / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D002317:Cardiovascular Agents